on BIOSYNEX (EPA:ALBIO)
BIOSYNEX begins safeguard proceedings, AVALUN ceases payment
BIOSYNEX SA has filed a request to open safeguard proceedings to restructure its bank debts with the Strasbourg Judicial Court. This decision comes amid an unfavorable economic climate in the United States and Europe. BIOSYNEX's revenue decreased by 6% in the first half of 2025 compared to 2024, reaching €50.8 million.
At the same time, its subsidiary AVALUN has declared insolvency. AVALUN, acquired in 2021, suffered from the termination of a remote biology project in 2023. Despite the interest generated by its technologies, notably the Tsmart® FIB Batrox test, the company faces significant financial challenges. BIOSYNEX is assessing the financial impacts of this situation, anticipating exceptional amortization of intangible assets and an uncollected receivable of €3.4 million.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOSYNEX news